Literature DB >> 29372582

Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.

Kentaro Takeda1, Satoshi Morita2.   

Abstract

We consider the problem of incorporating historical data from a preceding trial to design and conduct a subsequent dose-finding trial in a possibly different population of patients. In oncology, for example, after a phase I dose-finding trial is completed in Caucasian patients, investigators often conduct a further phase I trial to determine the maximum tolerated dose in Asian patients. This may be due to concerns about possible differences in treatment tolerability between populations. In this study, we propose to adaptively incorporate historical data into prior distributions assumed in a new dose-finding trial. Our proposed approach aims to appropriately borrow strength from a previous trial to improve the maximum tolerated dose determination in another patient population. We define a "historical-to-current (H-C)" parameter representing the degree of borrowing based on a retrospective analysis of previous trial data. In simulation studies, we examine the operating characteristics of the proposed method in comparison with 3 alternative approaches and assess how the H-C parameter functions across a variety of realistic settings.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian trial design; borrowing strength; dose finding; historical data; phase I clinical trial

Mesh:

Substances:

Year:  2018        PMID: 29372582     DOI: 10.1002/pst.1850

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment.

Authors:  Francesco De Pretis; Barbara Osimani
Journal:  Int J Environ Res Public Health       Date:  2019-06-24       Impact factor: 3.390

2.  Bridging across patient subgroups in phase I oncology trials that incorporate animal data.

Authors:  Haiyan Zheng; Lisa V Hampson; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2021-01-27       Impact factor: 3.021

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.